Timing
Purchase and sale flow
PurchasesSales
Stock, pipeline and biotech catalyst intelligence
Reported ownership activity
Activity signal
Reported purchases exceed sales by $106.3KOption exercises, awards, and grants are separated from open-market direction.Timing
Composition
Concentration
| Insider trading | Relationship | Date | Transaction | Cost | Shares | Value | Shares total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Coastlands Capital Lp | 10% Owner | Jul 14 '26 | Buy | $2.65 | 2,000 | $5,300 | 387,075 | Jul 16 05:08 PM |
| Coastlands Capital Lp | 10% Owner | Jul 16 '26 | Buy |
Company profile
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
| $2.75 |
| 1,233 |
| $3,391 |
| 388,308 |
| Jul 16 05:08 PM |
| Coastlands Capital Lp | 10% Owner | Jul 09 '26 | Buy | $2.79 | 10,053 | $28,048 | 383,375 | Jul 13 10:30 AM |
Transactions may include sales, purchases, grants, and option exercises. Directional charts count only purchases and sales; follow the Form 4 link to verify the original SEC filing.